| 翻訳と辞書 |
| Innogenetics ： ウィキペディア英語版 |
Innogenetics
Innogenetics N.V. (now Fujirebio Europe N.V.) is an international in vitro diagnostics (IVD) company, with headquarters in Ghent, Belgium. The company develops and markets IVD testing solutions from specialized manual testing to fully automated routine testing that cover areas such as infectious diseases, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone. The company was acquired in September 2010 by Japanese Fujirebio Inc., part of Miraca Holdings Inc., and changed name to Fujirebio Europe on October 1st 2013. The CEO of Fujirebio Europe N.V. is Christiaan De Wilde.
==History==
Innogenetics was founded on 18 July 1985, by Erik Tambuyzer, Hugo Van Heuverswyn and Rudi Mariën. In 1992, the company launched the first commercial tests for cystic fibrosis in Europe (INNO-LiPA CFTR) and in 1993 the first commercial test for Hepatitis C virus (HCV) genotyping worldwide (INNO-LiPA HCV). In 1995, the first commercial Alzheimer's disease research test for hTau was launched (INNOTEST hTau Ag). In 1998, the company launched the first commercial Alzheimer's disease research test for β-Amyloid and in 2002 the first commercial test for Hepatitis B virus (HBV) genotyping (INNO-LiPA HBV Genotyping).
The company was one of the first biotech companies to be listed on a European stock exchange, in 1996 it was the first biotech company listed on EASDAQ, now NASDAQ Europe. Until 2008 Innogenetics had its shares traded on Euronext Brussels.
Innogenetics N.V. was acquired by Fujirebio Inc., a Japanese daughter company of Miraca Holdings Inc., in 2010 and changed name to Fujirebio Europe N.V. on October 1st 2013.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Innogenetics」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|